Picture of Lunit logo

328130 — Lunit News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

Brief: Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development

BRIEF-Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development

- Lunit Inc. 328130.KQ:

  • SUMMIT THERAPEUTICS AND LUNIT ANNOUNCE AGREEMENT TO APPLY AI-POWERED SCOPE IO PLATFORM FOR TUMOR MICROENVIRONMENT ANALYSIS IN IMMUNO-ONCOLOGY DEVELOPMENT

Source text: ID:nBw3kD6jRa

Further company coverage: 328130.KQ


((((Reuters.Briefs@thomsonreuters.com;));))

Recent news on Lunit

See all news